title: Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
abstract: Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non-small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based on age.
  
  
  
  Data from patients randomized to paclitaxel-carboplatin (PC)+bevacizumab in the Eastern Cooperative Oncology Group 4599 (E4599) and PointBreak studies were pooled and compared with E4599 patients randomized to PC alone. Patients were grouped by age: below 65, 65 to 74, 70 to 74, below 75, and 75 years or above. A multivariable model was used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using time-to-event outcomes. Adverse events (AEs) were assessed by age group in each study.
  
  
  
  The PC+bevacizumab and PC arms comprised 901 and 444 patients, respectively. PC+bevacizumab was associated with significant increases in overall survival relative to PC in patients below 65 years (hazards ratio [HR], 0.75; 95% confidence interval [CI], 0.62-0.89), 65 to 74 years (HR, 0.80; 95% CI, 0.64-1.00), 70 to 74 years (HR, 0.68; 95% CI, 0.48-0.96), and below 75 years (HR, 0.78; 95% CI, 0.68-0.89) but not in those aged 75 years or above (HR, 1.05; 95% CI, 0.70-1.57). Increased incidence of grade ≥3 AEs was reported with PC+bevacizumab versus PC in patients below 75 years (63% vs. 48%; P<0.05) and 75 years or above (81% vs. 56%; P <0.05) in E4599.
  
  
  
  This analysis suggests that the survival benefits associated with PC+bevacizumab extend to patient subgroups below 75 years with advanced-stage NSCLC; no benefit, however, was observed for bevacizumab-eligible patients who were 75 years or above.
authors: *Abramson Cancer Center, University of Pennsylvania, Philadelphia †University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA ‡Feinberg School of Medicine, Northwestern University, Chicago, IL §Genentech Inc., South San Francisco, CA ∥Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX ¶Winship Cancer Institute of Emory University, Atlanta, GA.
authors: Corey J
authors: CJ
authors: Langer
authors: Mark A
authors: MA
authors: Socinski
authors: Jyoti D
authors: JD
authors: Patel
authors: Alan B
authors: AB
authors: Sandler
authors: Joan H
authors: JH
authors: Schiller
authors: Larry
authors: L
authors: Leon
authors: Sebastien J
authors: SJ
authors: Hazard
authors: Suresh S
authors: SS
authors: Ramalingam
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
references: Crit Rev Oncol Hematol. 2012 Nov;84(2):149-60
references: 22494932
references: J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
references: 10655437
references: J Thorac Oncol. 2009 Sep;4(9):1094-103
references: 19687765
references: Oncologist. 2013;18(4):408-14
references: 23576485
references: J Clin Oncol. 2008 Jan 1;26(1):60-5
references: 18165641
references: Chest. 2000 May;117(5):1239-46
references: 10807806
references: Cancer. 2003 Aug 15;98(4):779-88
references: 12910523
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Nat Rev Cancer. 2005 Aug;5(8):655-62
references: 16056261
references: Nat Med. 2003 Jun;9(6):669-76
references: 12778165
references: Oncologist. 2007 Jan;12(1):20-37
references: 17227898
references: J Thorac Oncol. 2010 Dec;5(12):1970-6
references: 20978447
references: J Clin Oncol. 2004 Dec 15;22(24):4971-8
references: 15611512
references: J Clin Oncol. 2005 Jun 1;23(16):3802-10
references: 15923574
references: N Engl J Med. 2002 Jan 10;346(2):92-8
references: 11784875
references: J Clin Oncol. 2013 Dec 1;31(34):4349-57
references: 24145346
references: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references: 19188680
references: J Thorac Oncol. 2012 Jan;7(1):203-11
references: 22173662
references: Drug Healthc Patient Saf. 2013 Apr 22;5:113-21
references: 23637560
references: Curr Treat Options Oncol. 2008 Dec;9(4-6):313-25
references: 18998213
references: J Natl Cancer Inst. 2002 Feb 6;94(3):173-81
references: 11830607
references: JAMA. 2012 Apr 18;307(15):1593-601
references: 22511687
references: Cancer. 2005 Dec 15;104(12):2766-74
references: 16288485
references: Breast Cancer Res Treat. 1995;36(2):127-37
references: 8534862
references: Oncologist. 2013;18(5):600-10
references: 23635558
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: Lung Cancer. 2011 Nov;74(2):326-31
references: 21481963